- £216.70bn
- £235.23bn
- $54.07bn
- 85
- 15
- 98
- 78
REG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in US for early gastric cancer
AnnouncementREG - AstraZeneca PLC - AstraZeneca manufacturing investment in Maryland
AnnouncementREG - AstraZeneca PLC - Koselugo (selumetinib) approved in the US
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - 9M and Q3 2025 results
AnnouncementREG - AstraZeneca PLC - Result of General Meeting
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - AstraZeneca PLC - Koselugo (selumetinib) approved in the EU
AnnouncementREG - AstraZeneca PLC - Tezspire Approved in EU for CRSwNP
AnnouncementREG - AstraZeneca PLC - US FDA Approves Tezspire in CRSwNP
AnnouncementREG - AstraZeneca PLC - Positive CHMP opinion for subcutaneous Saphnelo
AnnouncementREG - AstraZeneca PLC - Agreement with US Govt to lower medicine prices
AnnouncementRCS - LHH - LHH, EZRA's AI Leadership Transformation Program
AnnouncementREG - AstraZeneca PLC - Baxdrostat met primary endpoint in Bax24 Ph3 trial
AnnouncementREG - AstraZeneca PLC - Datroway improved OS and PFS in TROPION-Breast02
Announcement